Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); Q1 In-line; Waiting on P3 TIVO-1 Data at ASCO
Tweet
Share
E-mailGet Alerts AVEO Hot Sheet
Price: $15.00 --0%
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on AVEO Pharmaceuticals (NASDAQ: AVEO) price target of $14.00.
Analyst, Salveen Richter, said, "AVEO reported Q1/12 GAAP EPS of $(0.77), roughly in line with consensus of $(0.76) but below CGe of $(0.71). The call focused on ficlatuzumab P2 data in NSCLC, which was released yesterday, as well as management’s outlook for ASCO. We look toward full P3 TIVO-1 data at ASCO (June 2; 3pm-6pm; Chicago) – which will provide clarity on tivozanib’s efficacy and safety profile vs. the available drugs in RCC and in the context of new competitor data (PFE’s Inlyta) – to serve as the next catalyst for AVEO shares. The NDA filing remains on track for Q3/12." (Raising FY12 EPS estimate from $1.68 to $1.72)
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $11.55 yesterday.
Analyst, Salveen Richter, said, "AVEO reported Q1/12 GAAP EPS of $(0.77), roughly in line with consensus of $(0.76) but below CGe of $(0.71). The call focused on ficlatuzumab P2 data in NSCLC, which was released yesterday, as well as management’s outlook for ASCO. We look toward full P3 TIVO-1 data at ASCO (June 2; 3pm-6pm; Chicago) – which will provide clarity on tivozanib’s efficacy and safety profile vs. the available drugs in RCC and in the context of new competitor data (PFE’s Inlyta) – to serve as the next catalyst for AVEO shares. The NDA filing remains on track for Q3/12." (Raising FY12 EPS estimate from $1.68 to $1.72)
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $11.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Taylor Devices, Inc. (TAYD) to Buy
- BMO Capital Starts Skyworks Solutions (SWKS) at Market Perform
- BMO Capital Starts Analog Devices (ADI) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
